Evidence map›Paper›PMID 26528130›Full record

ReviewFrontiers in cellular neuroscience2015

Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy.

Yinghua Jiang, Xiang Fan, Zhanyang Yu, Zhengbu Liao, Xiao-Shu Wang, Klaus van Leyen, Xiaochuan Sun, Eng H Lo, Xiaoying Wang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yinghua JiangDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University , Chongqing , China ; Neuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
Xiang FanNeuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA ; Research Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine , Tianjin , China.
Zhanyang YuNeuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
Zhengbu LiaoDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University , Chongqing , China ; Neuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
Xiao-Shu WangDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University , Chongqing , China ; Neuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
Klaus van LeyenNeuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
Xiaochuan SunDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University , Chongqing , China.
Eng H LoNeuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
Xiaoying WangNeuroscience Program, Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
Harvard University · USMassachusetts General Hospital · USTianjin University of Traditional Chinese Medicine · CN

Funding

Development of annexin A2 plus tPA as a novel stroke thrombolytic therapyU01NS072324 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XIAOYING · 2011 to 2014
$2.2M
Recombinant annexin A2 plus tPA for combination stroke therapyR01NS065998 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XIAOYING · 2010 to 2014
$1.9M
NINDS NIH HHS R01 NS065998NINDS NIH HHS U01 NS072324
6 · The paper itself

Abstract

Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of low-dose tPA plus recombinant annexin A2 (rA2, a tPA, and plasminogen co-receptor), which might enhance tPA thrombolytic efficacy, while reducing its associated complications related to intracerebral hemorrhagic transformation. Results of our experimental studies using a focal embolic stroke model in rats support the feasibility of the combination approach and suggest the potential for successful clinical translation.

Indexed as

annexin A2cerebral ischemiacombination therapyfocal embolic stroke modelratsthrombolysistissue-type plasminogen activator

Identifiers

PMID26528130
PMCPMC4604305
OpenAlexW2199125063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.